Richard W Birkinshaw

15PUBLICATIONS
89CO-AUTHORS
Biologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Molecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Sep 05, 2025
Computational design of potent and selective binders of BAK and BAX.

Stephanie Berger, Erinna F Lee, Tiffany J Harris

|Jun 24, 2025
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.

Piers Blombery, Thomas Chatzikonstantinou, Marina Gerousi

|Apr 03, 2025
A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID.

Stefanie M Bader, Dale J Calleja, Shane M Devine

|Mar 05, 2025
Differential regulation of BAX and BAK apoptotic activity revealed by small molecules.

Kaiming Li, Yu Q Yap, Donia M Moujalled

|Oct 07, 2024
Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia.

Fiona C Brown, Xin Wang, Richard Birkinshaw

|May 02, 2024
Key residues in the VDAC2-BAK complex can be targeted to modulate apoptosis.

Zheng Yuan, Mark F van Delft, Mark Xiang Li

Pageof 3

Frequent Collaborators

9 joint publications

Peter E Czabotar

3 joint publications

David C S Huang

3 joint publications

Guillaume Lessene

2 joint publications

Michelle S Miller